Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

NCT02917772 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT02917772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02917772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2016
Completion date
October 31, 2022
Enrollment
200 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell, clear-cell metastatic renal cell carcinoma